The human ARF cell cycle regulatory gene promoter is a CPG island which can be silenced by DNA methylation and down-regulated by wild-type p53

Molecular and Cellular Biology

Volumn 18, Issue 11, 1998, Pages 6457-6473

  Robertson, Keith D ^a   Jones, Peter A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTION FACTOR SP1;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; REGULATOR GENE;

EID: 0031771497     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.18.11.6457     Document Type: Article

References (78)

1. Barak, Y., T. Juven, R. Haffner, and M. Oren. 1993. Mdm2 expression is induced by wild type p53 activity. EMBO J. 12:461-468.
2. Bender, C. M., M. M. Pao, and P. A. Jones. 1998. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58:95-101.
3. Bird, A. 1986. CpG-Rich islands and the function of DNA methylation. Nature 321:209-213.
4. Caldas, C., S. A. Hahn, L. T. daCosta, M. S. Redston, M. Schutte, A. B. Seymour, C. L. Weinstein, R. H. Hruban, C. J. Yeo, and S. E. Kern. 1994. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8:27-32.
5. Carcamo, J., L. Buckbinder, and D. Reinberg. 1991. The initiator directs the assembly of a transcription factor IID-dependent transcription complex. Proc. Natl. Acad. Sci. USA 88:8052-8056.
6. Chin, K.-V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Nature 255:459-462.
7. Corbin, V., and T. Maniatis. 1989. Role of transcriptional interference in the Drosophila melanogaster Adh promoter switch. Nature 337:279-282.
8. Crook, T., N. J. Marston, E. A. Sara, and K. H. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817-827.
9. DeGregori, J., G. Leone, A. Miron, L. Jakoi, and J. R. Nevins. 1997. Distinct rules for E2F proteins in cell growth control and apoptosis. Proc. Natl. Acad. Sci. USA 94:7245-7250.
10. Efstratiadis, A. 1994. Parental imprinting of autosomal mammalian genes. Curr. Opin. Genet. Dev. 4:265-280.
11. Fitzgerald, M. G., D. P. Harkin, S. Silva-Arrieta, D. J. MacDonald, L. C. Lucchina, H. Unsal, E. O'Neill, J. Koh, D. M. Finkelstein, K. J. Isselbacher, A. J. Sober, and D. A. Haber. 1996. Prevalence of germ-line mutations in p 16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc. Natl. Acad. Sci. USA 93:8541-8545.
12. Gardiner-Garden, M., and M. Frommer. 1987. CpG islands in vertebrate genomes. J. Mol. Biol. 196:261-282.
13. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-regulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88:9979-9983.
14. Gonzalez-Zulueta, M., C. M. Bender, A. S. Yang, T.-D. Nguyen, R. W. Beart, J. M. VanTornout, and P. A. Jones. 1995. Methylation of the CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res. 55: 4531-4535.
15. Gonzalgo, M. L., T. Hayashida, C. M. Bender, M. M. Pao, Y. C. Tsai, F. A. Gonzales, H. D. Nguyen, T.-D. Nguyen, and P. A. Jones. 1998. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res. 58:1245-1252.
16. ARF. Cell 91:555-558.
17. Hall, M., and G. Peters. 1996. Genetic alterations of cyclins, cyclin-dependent kinases, and cdk inhibitors in human cancer. Adv. Cancer Res. 68:67-108.
18. CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol. 16:859-867.
19. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
20. INK4B. Cancer Res. 54:722-727.
21. Herman, J. G., A. Merlo, L. Mao, R. G. Lapidus, J. P. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin. 1995. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55:4525-4530.
22. Hollstein, M., K. Rice, M. S. Greenblatt, T. Soussi, R. Fuchs, T. Sorlie, E. Hovig, B. Smith-Sorensen, R. Montesano, and C. C. Harris. 1994. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 22:3551-3555.
23. Hussussian, C. J., J. P. Struewing, A. M. Goldstein, P. A. T. Higgins, D. S. Ally, M. D. Sheahan, W. H. Clark, M. A. Tucker, and N. C. Dracopoli. 1994. Germline p16 mutations in familial melanoma. Nat. Genet. 8: 15-21.
24. Jones, N. C., P. W. Rigby, and E. B. Ziff. 1988. Trans-acting protein factors and the regulation of eukaryotic transcription: lessons from studies on DNA tumor viruses. Genes Dev. 2:267-281.
25. Jones, P. A., M. J. Wolkowicz, W. M. Rideout III, F. A. Gonzales, C. M. Marziasz, G. Coetzee, and S. J. Tapscott. 1990. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines. Proc. Natl. Acad. Sci. USA 87:6117-6121.
26. Kamb, A., D. Shattuck-Eidens, R. Eeles, Q. Liu, N. A. Gruis, W. Ding, C. Hussey, T. Tran, Y. Miki, J. Weaver-Feldhaus, M. McClure, J. F. Aitken, D. E. Anderson, W. Bergman, R. Frants, D. E. Goldgar, A. Green, R. MacLennan, N. G. Martin, L. J. Meyer, P. Youl, J. J. Zone, M. H. Skolnick, and L. A. Cannon-Albright. 1994. Analysis of the p 16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet. 8: 22-26.
27. ARF. Cell 91:649-659.
28. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
29. Ko, L. J., and C. Prives. 1996. p53: Puzzle and paradigm. Genes Dev. 10: 1054-1072.
30. Kubbutat, M. H. G., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by mdm2. Nature 387:299-303.
31. INK4a: a gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene 12:2041-2044.
32. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
33. Liggett, W. H., D. A. Sewell, J. Rocco, S. A. Ahrendt, W. Koch, and D. Sidransky. 1996. p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res. 56:4119-4123.
34. Mack, D. H., J. Vartikar, J. M. Pipas, and L. A. Laimins. 1993. Specific repression of TATA-mediated but not initiator-mediated transcription repression by wild-type p53. Nature 363:281-283.
35. Macleod, D., J. Charlton, J. Mullins, and A. P. Bird. 1994. Sp1 sites in the mouse Aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev. 8:2282-2292.
36. INK4A transcript. Cancer Res. 55: 2995-2997.
37. Means, A. L., and P. J. Farnham. 1990. Transcriptional initiation from the dihydrofolate reductase promoter is positioned by HIP-1 binding at the initiation site. Mol. Cell. Biol 10:653-661.
38. Mercer, W. E., M. T. Shields, D. Lin, E. Appella, and S. J. Ullrich. 1991. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Natl. Acad. Sci. USA 88:1958-1962.
39. Merlo, A., J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. Burger, S. B. Baylin, and D. Sidransky. 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:686-692.
40. Moran, E. 1993. DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genet. Dev. 3:63-70.
41. Nelson, W. G., and M. B. Kastan. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol. Cell. Biol. 14:1815-1823.
42. Oliner, J. D., K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83.
43. Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857-860.
44. Parry, D., S. Bates, D. J. Mann, and G. Peters. 1995. Lack of cyclin D-cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumor suppressor gene product. EMBO J. 14:503-511.
45. Perry, M. E., and A. J. Levine. 1993. Tumor-suppressor p53 and the cell cycle. Curr. Opin. Genet. Dev. 3:50-54.
46. Pietenpol, J. A., T. Tokino, S. Thiagalingam, W. El-Deiry, K. W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. USA 91: 1998-2002.
47. Polyak, K., T. Waldman, T.-C. He, K. W. Kinzler, and B. Vogelstein. 1996. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 10:1945-1952.
48. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723.
49. Proudfoot, N. J. 1986. Transcriptional interference and termination between duplicated α-globin gene constructs suggests a novel mechanism for gene regulation. Nature 322:562-565.
50. Puglielli, M. T., N. Desai, and S. H. Speck. 1997. Regulation of EBNA gene transcription in lymphoblastoid cell lines: characterization of sequences downstream of BCR2 (Cp). J. Virol. 71:120-128.
51. ARF. Proc. Natl. Acad. Sci. USA 94:669-673.
52. Quelle, D. E., F. Zindy, R. A. Ashmun, and C. J. Sherr. 1995. Alternative reading frames of the INKAa tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
53. Rashbaum, S. A., and N. R. Cozzarelli. 1976. Mechanism of DNA synthesis inhibition by arabinosyl cytosine and arabinosyl adenine. Nature 264:679.
54. Reich, N. C., and A. J. Levine. 1984. Growth regulation of a cellular tumor antigen. p53, in nontransformed cells. Nature 308:199-201.
55. Robertson, K. D., and R. F. Ambinder. 1997. Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. J. Virol. 71:6445-6454.
56. Robertson, K. D., S. D. Hayward, P. D. Ling, D. Samid, and R. F. Ambinder. 1995. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol. Cell. Biol. 15:6150-6159.
57. Rozenblum, E., M. Schutte, M. Goggins, S. A. Hahn, S. Panzer, M. Zahurak, S. N. Goodman, T. A. Sohn, R. H. Hruban, C. J. Yeo, and S. E. Kern. 1997. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57:1731-1734.
58. Santhanam, U., A. Ray, and P. B. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. USA 88:7605-7609.
59. Schutte, M., R. H. Hruban, J. Geradts, R. Maynard, W. Hilgers, S. K. Rabindran, C. A. Moskaluk, S. A. Hahn, I. Schwarte-Waldhoff, W. Schmiegel, S. B. Baylin, S. E. Kern, and J. G. Herman. 1997. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57:3126-3130.
60. Serrano, M., G. J. Hannon, and D. Beach. 1993. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707.
61. Serrano, M., H.-W. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.
62. Seto, E., A. Usheva, G. P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A. J. Levine, and T. Shenk. 1992. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc. Natl. Acad. Sci. USA 89: 12028-12032.
63. Sewell, D. A., W. H. Liggett, Jr., W. G. Yarbrough, and D. Sidransky. 1997. Human p16β encodes a novel 14 kD protein and suppresses growth in vitro independently from pRb. Proc. Am. Assoc Cancer Res. 38:80.
64. Sherr, C. J. 1996. Cancer cell cycles. Science 276:1672-1677.
65. Shores, C., E. Liu, and W. Yarbrough. 1997. Expression of p16β in human cells. Proc. Am. Assoc. Cancer Res. 38:277.
66. Shrivastava, A., and K. Calame. 1994. An analysis of genes regulated by the multi-functional transcriptional regulator Yin Yang-1. Nucleic Acids Res. 22:5151-5155.
67. Smale, S. T., and D. Baltimore. 1989. The "initiator" as a transcriptional control element. Cell 57:103-113.
68. Stone, S., P. Jiang, P. Dayananth, S. V. Tavtigian, H. Katcher, D. Parry, G. Peters, and A. Kamb. 1995. Complex structure and regulation of the p16 (MTS1) locus. Cancer Res. 55:2988-2994.
69. Subler, M. A., D. W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66:4757-4762.
70. INK4. Cancer Res. 54:5816-5820.
71. Tanaka, H., Y. Shimada, M. Imamura, I. Shabagaki, and K. Ishizaki. 1997. Multiple types of aberrations in the p16(INK4a) and the p15(INK4b) genes in 30 esophageal squamous-cell-carcinoma cell lines. Int. J. Cancer 70:437-442.
72. Trimarchi, J. M., B. Fairchild, R. Verona, K. Moberg, N. Andon, and J. A. Lees. 1998. E2F-6. a member of the E2F family that can behave as a transcriptional repressor. Proc. Natl. Acad. Sci. USA 95:2850-2855.
73. Tuck, S. P., and L. Crawford. 1989. Characterization of the human p53 gene promoter. Mol. Cell. Biol. 9:2163-2172.
74. Vales, L. D., and J. E. Darnell. 1989. Promoter occlusion prevents transcription of Adenovirus polypeptide IX mRNA until after DNA replication. Genes Dev. 3:49-59.
75. Wu, J., G. J. Grindlay, P. Bushel, L. Mendelsohn, and M. Allan. 1990. Negative regulation of the human ε-globin gene by transcriptional interference: role of an Alu repetitive element. Mol. Cell. Biol. 10:1209-1216.
76. Wu, X., J. H. Bayle, D. Olsen, and A. J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126-1132.
77. Xu, Z.-P., and G. F. Saunders. 1997. Transcriptional regulation of the human PAX6 gene promoter. J. Biol. Chem. 272:3430-3436.
78. Zhang, Y., Y. Xiong, and W. G. Yarbrough. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734.